Featured Story | | | Tuesday, September 5, 2017 The FDA has placed a clinical hold on two phase 1 trials of Cellectis’ UCART123 after learning of the death of one patient. Development of the off-the-shelf CAR-T therapy is now in limbo while Cellectis works with the FDA to redesign the protocol to mitigate the risks identified in the first weeks of the trials. |
|
|
Top Stories Tuesday, September 5, 2017 With CAR-T therapies now reaching the market, Japanese drugmaker Takeda has made a play to grab a slice of the pie via a deal with biotech startup Noile-Immune. Tuesday, September 5, 2017 Destiny Pharma has listed on London’s AIM exchange. The IPO gives Destiny £15.3 million ($19.8 million) to assess lead candidate XF-73 in the prevention of post-surgical staphylococcal infections in a phase 2b trial. Tuesday, September 5, 2017 OrbiMed has launched its third Asia-focused biopharma and healthcare fund with more than half a billion dollars’ worth of private equity. Tuesday, September 5, 2017 Most research efforts aimed at Zika virus seek to kill the pathogen. But researchers at Washington University School of Medicine in St. Louis and the University of California at San Diego are turning the anti-Zika pursuit on its head, finding a potentially useful role for the virus in treating gliobastoma. Monday, August 28, 2017 The life sciences field presents its own barriers to women's advancement, but in spite of these challenges, women can and do attain top-level positions, start their own companies and otherwise make their marks on the industry. Know a woman in biotech, pharma or medtech who is doing just that? Nominate her for this year's Fiercest Women in Life Sciences feature. Tuesday, September 5, 2017 Novartis' drug-development chief, Vas Narasimhan, will take over as CEO in February 2018 from Joe Jimenez, who is retiring. Narasimhan will enjoy the fruits of Novartis' groundbreaking FDA approval of the first CAR-T treatment for cancer, but he will also be inheriting several challenges, not the least of which is pricing pressure on both branded and generic drugs. | This week's sponsor is FierceBiotech. | | | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Resources Presented By: Decision Resources Group
Uncover the true power of patient-centric data with this valuable industry resource. Click here to discover more Sponsored by: Ashfield Healthcare
Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences
Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Sponsored By: RTI Health Solutions
In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.
2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Now Accepting Applications: Fierce Innovation Awards Life Science Edition Compliance Certificate and Training for Life Sciences Professionals October 9 -12, 2017 | Newark, NJ FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 